- English (USA)
- English (India)
- English (Canada)
- English (Australia)
- English (South Africa)
- English (Philippines)
- English (Nigeria)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Português (Portugal)
- Polski
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
United Therapeutics Corporation (UTHR)
Assess today's live United Therapeutics Corporation (UTHR) share price, performance and insights using our live NASDAQ: UTHR stock exchange data.
Analyse the historical data and United Therapeutics Corporation share price performance charts on this page. Our technical summary section provides analysis on United Therapeutics share price buy/sell indicators using real-time data (or discuss the United Therapeutics (UTHR) stock price today with other investors in the United Therapeutics NASDAQ share price and sentiment chat forum).
Use the dropdown to select a relevant stock exchange for the current NASDAQ UTHR share price (ISIN: US91307C1027) to enhance your trading decisions with our free investment tools and resources.
What Is the United Therapeutics Corporation Share Price Today?
The United Therapeutics share price today is 291.72.
What Is the Stock Symbol for United Therapeutics Corporation
The stock symbol (or 'ticker') for United Therapeutics Corporation is "UTHR."
What Stock Exchange Does United Therapeutics Corporation Trade On?
United Therapeutics Corporation is listed and trades on the NASDAQ stock exchange.
Is United Therapeutics Corporation a Good Stock to Buy?
Determining whether United Therapeutics Corporation—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, investors can sign up to InvestingPro, where they can assess share price, fair value and other essential metrics.
Analyse the historical data and United Therapeutics Corporation share price performance charts on this page. Our technical summary section provides analysis on United Therapeutics share price buy/sell indicators using real-time data (or discuss the United Therapeutics (UTHR) stock price today with other investors in the United Therapeutics NASDAQ share price and sentiment chat forum).
Use the dropdown to select a relevant stock exchange for the current NASDAQ UTHR share price (ISIN: US91307C1027) to enhance your trading decisions with our free investment tools and resources.
What Is the United Therapeutics Corporation Share Price Today?
The United Therapeutics share price today is 291.72.
What Is the Stock Symbol for United Therapeutics Corporation
The stock symbol (or 'ticker') for United Therapeutics Corporation is "UTHR."
What Stock Exchange Does United Therapeutics Corporation Trade On?
United Therapeutics Corporation is listed and trades on the NASDAQ stock exchange.
Is United Therapeutics Corporation a Good Stock to Buy?
Determining whether United Therapeutics Corporation—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, investors can sign up to InvestingPro, where they can assess share price, fair value and other essential metrics.
NASDAQ
Currency in USD
291.72
+4.84(+1.69%)
Closed·
After Hours
292.00+0.28(+0.10%)
·
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
282.89
292.74
52 wk Range
266.98
417.82
UTHR Scorecard
Full Analysis
Has a perfect Piotroski Score of 9
UTHR is not included in our AI-picked strategies. See which stocks are.
Review Strategies
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
282.89292.74
52 wk Range
266.98417.82
Key Statistics
Edit
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
UTHR Scorecard
Company’s Health
Assesses a company's financial position by analysing its market value, financial ratios, industry benchmarks, and competitors.
UnlockFair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Unlock PriceTechnical Analysis
Strong Sell
Price Target
382.09
Upside
+30.98%
Members' Sentiments
Bearish
Bullish
ProTips
Tips that distill complex financial data into concise, actionable investment insights.
Holds more cash than debt on its balance sheet
United Therapeutics Company Profile
United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients. It also markets and sells Unituxin (dinutuximab) injection, a monoclonal antibody for treating high-risk neuroblastoma; and Remunity Pump, which contains a pump and separate controller for Remodulin. In addition, the company involved in developing RemoPro and Ralinepag for the treatment of PAH; Aurora-GT, a gene therapy product to rebuild the blood vessels in the lungs; and Nebulized Tyvaso, for the treatment of idiopathic pulmonary fibrosis, as well as xenografts, which are development-stage organ products. It has licensing and collaboration agreements with DEKA Research & Development Corp. to develop a semi-disposable system for the subcutaneous delivery of treprostinil; MannKind Corporation to develop and license treprostinil inhalation powder and the Dreamboat device; and Arena Pharmaceuticals, Inc. to develop Ralinepag. United Therapeutics Corporation was incorporated in 1996 and is headquartered in Silver Spring, Maryland.
United Therapeutics Corporation Earnings Call Summary for Q1/2025
- United Therapeutics reported Q1 2025 EPS of $6.63, beating $6.53 forecast, with revenue of $794.4M exceeding $728.34M estimate
- Company achieved 17% YoY revenue growth, marking 11 consecutive quarters of double-digit growth across all treprostinil products
- Despite strong earnings, stock declined 0.47% in pre-market trading; company maintains 89.24% gross profit margin and 13x P/E ratio
- CEO highlighted disciplined financial approach, never spending over 50% of prior year revenue on cash operating expenses
- Future outlook includes continued double-digit revenue growth, uKidney transplant study, and potential Ralinepag commercialization
Last Updated: 30/04/2025, 15:02
Read Full TranscriptCompare UTHR to Peers and Sector
Metrics to compare | UTHR | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipUTHRPeersSector | |
|---|---|---|---|---|
P/E Ratio | 10.9x | −5.0x | −0.5x | |
PEG Ratio | 0.58 | −0.05 | 0.00 | |
Price/Book | 1.9x | 2.3x | 2.6x | |
Price / LTM Sales | 4.4x | 2.4x | 3.0x | |
Upside (Analyst Target) | 37.1% | 392.4% | 51.5% | |
Fair Value Upside | Unlock | 22.1% | 9.4% | Unlock |
Analyst Ratings
9 Buy
6 Hold
0 Sell
Ratings:
15 analysts
Overall Consensus
Buy
Analysts 12-Month Price Target:
Average 382.09
(+30.98% Upside)
Earnings
Latest Release
Apr 30, 2025
EPS / Forecast
6.63 / 6.53
Revenue / Forecast
794.40M / 728.34M
People Also Watch
FAQ
What Is the United Therapeutics (UTHR) Share Price Today?
The live United Therapeutics share price today is 291.72.
What Stock Exchange Does United Therapeutics (UTHR) Trade On?
United Therapeutics is listed and trades on the Nasdaq Stock Exchange stock exchange.
What Is the Ticker (Stock Symbol) for United Therapeutics?
The stock symbol (also called a 'ticker') for United Therapeutics is "UTHR."
What Is the Current United Therapeutics Market Cap?
As of today, United Therapeutics market capitalisation is 13.16B.
What Is United Therapeutics's (UTHR) Earnings Per Share (TTM)?
The United Therapeutics EPS 27.10 (Trailing Twelve Months).
When Is the Next United Therapeutics Earnings Date?
United Therapeutics's next earnings report will be released on 29 Jul 2025.
Is UTHR a Buy or Sell From a Technical Analyst Perspective?
Based on today's United Therapeutics moving averages and other technical indicators, the daily buy/sell signal is Strong Sell.
How Many Times Has United Therapeutics Stock Split?
United Therapeutics has split 1 times. (See the UTHR stock split history page for full effective split date and price information.)
How Many Employees Does United Therapeutics Have?
United Therapeutics currently has 1305 employees.
What is the current trading status of United Therapeutics (UTHR)?
As of 19 Jun 2025, United Therapeutics (UTHR) is trading at a price of 291.72, with a previous close of 286.88. The stock has fluctuated within a day range of 282.89 to 292.74, while its 52-week range spans from 266.98 to 417.82.
Install Our App
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2025 - Fusion Media Limited. All Rights Reserved.